Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Molecular test predicts recurrence risk and who will benefit from chemotherapy
December 28th, 2004
A new test can predict both the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy, according to research supported by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health, and performed in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health Inc. These results suggest that almost half of over 50,000 U.S. women diagnosed with estrogen-dependent, lymph-node negative breast cancer (tumor size >1 cm, <5 cm) every year are at low risk for recurrence and may not need to go through the discomfort and side effects of chemotherapy. ...
Source: Cancer Weekly (2004-12-28)
|
